Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment

Phase 2

Completed

• Conditions: Coronavirus Infection; COVID-19
• Interventions: Drug: Chloroquine or Hydroxychloroquine

• Registration Number: NCT04353336
• Lead Sponsor: Tanta University

Brief Summary

Chloroquine or hydroxychloroquine in COVID-19 treatment

Detailed Description

Clinical Study Evaluating the Efficacy of Chloroquine or hydroxychloroquine in COVID-19 treatment

Study Timeline

• Study Start: 2020-03-23
• Study First Submitted: 2020-04-15
• Study First Submitted QC: 2020-04-17
• Study First Posted: 2020-04-20
• Primary Completion: 2020-06-01
• Study Completion: 2020-07-01
• Status Verified: 2021-07
• Last Update Submitted: 2021-07-29
• Last Update Posted: 2021-08-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 194

Inclusion Criteria

• Covid 19 patients

Exclusion Criteria

• Allergy or contraindication to the drug
• Pregnant or lactating
• Patients with cardiac problems

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Chloroquine or Hydroxychloroquine	Chloroquine or Hydroxychloroquine	Chloroquine or Hydroxychloroquine with standard of care treatment.

Primary Outcome Measures

Name	Time	Method
Number of patients with cure or death	1 month	the number of patients with cure or death

Trial Locations

Locations (1)

Tanta University, Assiut University; 🇪🇬 Tanta, Egypt